COA Research and Manufacturing Limited Company sets record straight on Coa-72 clinical trials

The management of COA Research and Manufacturing Limited Company (COARMLC) wishes to clarify recent media reports regarding the status of COA- 72, following a publication in the Daily Graphic on Wednesday, July 16, 2025, headlined: “COA-72 undergoes clinical trials as anti-HIV drug.”

This statement is issued to address misinformation contained in the said article and to reaffirm our unwavering commitment to scientific integrity, regulatory compliance and transparent communication with the public.

• Read also:
• Parliamentary Select Committee on Health pledges advocacy support for COA RMCL’s research
• FDA Ghana’s disclaimer on purported approval of COA 72 for clinical trials as an anti-HIV drug

1. Clarification on Media Reports

On Monday, July 14, 2025, the Parliamentary Select Committee on Health paid a working visit to COARMLC’s facilities. During the visit, management engaged with committee members on the company’s ongoing research and development efforts. Unfortunately, the subsequent media reportage by the Daily Graphic inaccurately suggested that COA-72 is currently undergoing clinical trials for HIV treatment.

To address this, COARMLC notified Daily Graphic regarding the wrong reportage and a rejoinder was issued, which was published in the Daily Graphic on Thursday, July 17, 2025. We appreciate the Food and Drugs Authority (FDA) Ghana for further issuing a disclaimer affirming that no such clinical trial involving COA-72 has been approved for HIV treatment, which aligns with COARMLC’s position.

2. Background and Research Journey

During the interaction with the committee members, COARMLC’s Founder and CEO, Mr Samuel Ato Duncan, shared the personal and professional journey that has driven the company’s research initiatives:

• On 30th November 2005, Mr Duncan publicly committed to pursuing a natural cure for HIV. 

 • This vision led to extensive research in plant-based medicine and the development of key products, including COA Mixture, COA Plus Mixture, COA-MT Mixture and COA Capsules.

• While these products are not intended or approved for HIV treatment, the research laid the foundation for the development of COA-72, a new formulation believed — based on preliminary studies — to have properties that may fight viral infections and cancers.

3. Introducing COA-72: A Call for National Support

At no point during the meeting with the Parliamentary Select Committee did COARMLC claim that COA-72 was undergoing FDA-approved clinical trials. Rather, management took the opportunity to:

• Introduce COA-72 as a promising formulation based on internal and collaborative research findings.

• Highlight the need for further, scientifically rigorous studies.

• Appeal for government and institutional support to initiate formal clinical trials, which require significant investment and technical resources.